FREDDY ALI: Open Payments
NPI 1851504922 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$66,722 in 137 payments from 9 companies in 2025. Trend: 2023 $11,472 · 2024 $27,451 · 2025 $66,722
Speaker / faculty: $31,920Consulting: $25,105Travel & lodging: $6,423Food & beverage: $3,275
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 60 | $34,069 |
| E.R. Squibb & Sons, L.L.C. | 28 | $15,318 |
| Teva Pharmaceuticals USA, Inc. | 6 | $9,306 |
| Alkermes, Inc. | 17 | $7,563 |
| ABBVIE INC. | 11 | $159 |
| Otsuka America Pharmaceutical, Inc. | 8 | $154 |
| Janssen Pharmaceuticals, Inc | 5 | $121 |
| Almatica Pharma LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: INGREZZA, LYBALVI, COBENFY, UZEDY, VRAYLAR, REXULTI, INVEGA SUSTENNA, ARISTADA.
Industry payments across PA — which companies pay providers there.
